Sugi Predict

Sugi Predict / Compounds / SCHEMBL371876

SCHEMBL371876

SCHEMBL371876

COc1cc2c(Oc3ncc(NC(=O)CC(=O)Nc4ccc(F)cc4)cc3Cl)ccnc2cc1OCCCN1CCOCC1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MET P08581 14/20 0.69
▸ KDR P35968 4/20 0.69
▸ FLT3 P36888 4/20 0.67
▸ EGFR P00533 3/20 0.67
▸ RPS6KB1 P23443 3/20 0.67
▸ TEK Q02763 3/20 0.67
▸ MST1R Q04912 3/20 0.67
▸ BTK Q06187 3/20 0.67
▸ AXL P30530 3/20 0.67
▸ AURKA O14965 2/20 0.67
▸ JAK2 O60674 2/20 0.67
▸ LCK P06239 2/20 0.67
▸ FLT1 P17948 2/20 0.67
▸ FGFR2 P21802 2/20 0.67
▸ FLT4 P35916 2/20 0.67
▸ MAPK9 P45984 2/20 0.67
▸ PLK4 O00444 1/20 0.67
▸ STK25 O00506 1/20 0.67
▸ CIT O14578 1/20 0.67
▸ CHUK O15111 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19711782 0.93 MET (0.64) METKDRFLT3EGFRRPS6KB1
SCHEMBL371858 0.93 MET (0.61) METKDRFLT3EGFRRPS6KB1
SCHEMBL1877060 0.88 MET (0.84) METKDRFLT3EGFRRPS6KB1
SCHEMBL4473129 0.88 KDR (0.59) METKDRFLT3EGFRMST1R
SCHEMBL20525647 0.86 MET (0.52) METKDRFLT3EGFRRPS6KB1
SCHEMBL371549 0.86 AXL (0.67) METKDRFLT3EGFRTEK
SCHEMBL12443897 0.85 MET (0.60) METKDRFLT3EGFRRPS6KB1
SCHEMBL371718 0.84 AXL (0.57) METKDRFLT3EGFRTEK
SCHEMBL4414994 0.83 MET (0.58) METKDRFLT3EGFRRPS6KB1
SCHEMBL29693565 0.83 AXL (0.56) METKDRFLT3EGFRTEK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210253530-A9 C-MET MODULATORS AND METHODS OF USE EXELIXIS, INC. 2021-08-19 — — US claimed
US-20200331860-A1 C-Met Modulators and Methods of Use EXELIXIS INC (US) 2020-10-22 — — US claimed
EP-2101759-B1 METHODS OF USING MEK INHIBITORS EXELIXIS INC (US) 2018-10-10 — — EP claimed
US-20170355678-A1 C-Met Modulators and Methods of Use EXELIXIS INC (US) 2017-12-14 — — US claimed
US-20160185725-A1 c-Met Modulators and Method of Use EXELIXIS, INC. 2016-06-30 — — US claimed
US-20150376133-A1 C-Met Modulators and Methods of Use EXELIXIS, INC. 2015-12-31 — — US claimed
US-20120022065-A1 C-Met Modulators and Method of Use EXELIXIS, INC. (US) 2012-01-26 — — US claimed
WO-2009017838-A2 COMBINATIONS OF JAK-2 INHIBITORS AND OTHER AGENTS EXELIXIS, INC. (US) 2009-02-05 — — WO claimed
US-20070054928-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2007-03-08 — — US claimed
EP-3329918-B1 C-MET MODULATORS AND METHODS OF USE EXELIXIS INC (US) 2022-05-25 — — EP disclosed
US-11124482-B2 C-met modulators and methods of use EXELIXIS, INC. (US) 2021-09-21 — — US disclosed
US-11124482-B2 C-met modulators and methods of use EXELIXIS, INC. (US) 2021-09-21 — — US disclosed
US-20210253530-A9 C-MET MODULATORS AND METHODS OF USE EXELIXIS, INC. 2021-08-19 — — US disclosed
US-20210253530-A9 C-MET MODULATORS AND METHODS OF USE EXELIXIS, INC. 2021-08-19 — — US disclosed
US-20070225307-A1 C-MET MODULATORS AND METHOD OF USE EXELIXIS, INC. (US) 2007-09-27 — — US disclosed
US-20070225307-A1 C-MET MODULATORS AND METHOD OF USE EXELIXIS, INC. (US) 2007-09-27 — — US disclosed
US-20070225307-A1 C-MET MODULATORS AND METHOD OF USE EXELIXIS, INC. (US) 2007-09-27 — — US disclosed
US-20070054928-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2007-03-08 — — US disclosed
US-20070054928-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2007-03-08 — — US disclosed
US-20070054928-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2007-03-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200331860-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET MET 3/4885KDR 4/4885FLT3 7/4885
US-20070054928-A1 c-Met modulators and methods of use FLT4, FLT1, MET MET 3/4885KDR 4/4885FLT3 7/4885
US-20120022065-A1 C-Met Modulators and Method of Use FLT4, MET, FLT1 MET 2/4885KDR 5/4885FLT3 7/4885
US-20150376133-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET MET 3/4885KDR 4/4885FLT3 7/4885
US-20170355678-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET MET 3/4885KDR 4/4885FLT3 7/4885
US-20210253530-A9 C-MET MODULATORS AND METHODS OF USE FLT4, FLT1, MET MET 3/4885KDR 4/4885FLT3 7/4885
US-20070225307-A1 C-MET MODULATORS AND METHOD OF USE FLT4, MET, FLT1 MET 2/4885KDR 5/4885FLT3 7/4885
US-20160185725-A1 c-Met Modulators and Method of Use FLT4, MET, FLT1 MET 2/4885KDR 5/4885FLT3 7/4885
US-11124482-B2 C-met modulators and methods of use FLT4, FLT1, MET MET 3/4885KDR 4/4885FLT3 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.